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Th  e clinical study by van der Boogaard and colleagues 
recently published in Critical Care [1] was designed to 
unravel some of the open questions regarding the patho-
physiology of septic encephalopathy. Th   e authors mimicked 
inﬂ  ammation-associated encephalopathy by induction of 
experimental endotoxemia using Escheria coli-derived 
lipopolysaccharides (LPSs) in 15 healthy young volun-
teers. Outcome parameters were serum levels of cyto-
kines, cortisol, neuron speciﬁ  c enolase, S100-β, as well as 
electroencephalographic changes and cognitive function 
in comparison to a healthy cohort of ten control volun-
teers. Interestingly, van der Boogaard and colleagues 
described that the endotoxin-induced ‘cytokine storm’ 
and cortisol release failed to provoke any signs of septic 
encephalopathy [1]. No clinically relevant electro  encepha-
lo  graphic changes occurred, and markers of neuronal 
damage (neuron speciﬁ  c enolase, S100-β) were found to 
be slightly reduced following LPS challenge. Endotoxemia 
even resulted in a higher state of alertness and improved 
cognitive function in comparison to the healthy cohort. 
Th   e authors concluded that tem  porary systemic inﬂ  am-
ma  tion caused by endo  toxemia cannot provoke the 
develop ment  of  septic encephalopathy. Nonetheless, their 
present study shed some further light towards our under-
standing of the immunological pathophysiology of septic 
encephalo pathy,  as  it appears unlikely that bacterial LPS 
is a driving force in the development of septic encephalo-
pathy. Note  worthy, the spectrum of responsible micro-
organisms has shifted from predominantly Gram-
negative bacteria in the late 1970s and 1980s to predomi-
nantly Gram-positive bacteria and fungal infections at 
present [2].
Th  e authors’ ﬁ  ndings underscore the complexity and 
ambiguity of septic encephalopathy, which continues to 
be a puzzling complication of the sepsis syndrome. Th  is 
is of particular concern, as up to 70% of all septic patients 
develop signs of such brain damage [3]. Traditionally, 
septic encephalopathy was thought to occur due to 
inﬂ   ammatory breakdown of the blood-brain barrier 
(BBB) as a ‘key’ causative factor of sepsis-associated 
delirium [3]. A dysfunction of the BBB has been shown to 
be induced by various inﬂ  ammatory mediators, such as 
IL-1β, TNF-α, complement, and bradykinin, which can 
cause a ‘sterile meningitis’ in the absence of a bacterial 
pathogen [4,5]. Moreover, complement C3 and C5a have 
been linked to sepsis-induced compromise of the BBB 
[6]. Of note, direct contact between blood and cerebro-
spinal ﬂ  uid leads to complement activation, as may be the 
case in severe BBB dysfunction [7]. Th   e disruption of this 
physical barrier then allows circulating neurotoxic sub-
stances to extravasate into the brain parenchyma and 
promote an inﬂ   ammatory response. However, this 
traditional notion of initial BBB compromise prior to 
development of septic encephalopathy has recently been 
challenged [8]. In their experimental study, Londoño and 
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The exact cellular and molecular mechanisms of 
sepsis-induced encephalopathy remain elusive. 
The breakdown of the blood-brain barrier (BBB) 
is considered a focal point in the development of 
sepsis-induced brain damage. Contributing factors 
for the compromise of the BBB include cytokines and 
chemokines, activation of the complement cascade, 
phagocyte-derived toxic mediators, and bacterial 
products. To date, we are far from fully understanding 
the neuropathology that develops as a secondary 
remote organ injury as a consequence of sepsis. 
Howver, recent studies suggest that bacterial proteins 
may readily cross the functional BBB and trigger an 
infl  ammatory response in the subarachnoid space, in 
absence of a bacterial invasion. A better understanding 
of the pathophysiological events leading to septic 
encephalopathy appears crucial to advance the clinical 
care for this vulnerable patient population.
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outer membrane lipoproteins of Borellia turicatae and 
monitored their localization in the brain. Surprisingly, 
two of the lipoproteins studied (LVsp1 and LVsp2) were 
capable of disseminating from the periphery into the 
brain and caused intracerebral inﬂ  ammation  without 
intracerebral spirochete accumulation [8]. Th  ese  ﬁ  ndings 
provide novel insights into the potential development of 
septic encephalopathy. Another piece of the complex 
puzzle of septic encephalopathy may be the extensive 
communication between the nervous and the immune 
system. Interestingly, this interaction is bi-directional, as 
cytokines can trigger the release of glucocorticoids via 
the hypothalamic-pituitary axis, and, in turn, gluco  corti-
coids suppress cytokine synthesis of leukocytes [9]. 
Moreover, both systems use a common biochemical 
language of hormones, ligands and receptors to commu-
nicate with each other [10,11]. In the setting of sepsis, the 
majority of work in neuroimmunology has focused on 
the anti-inﬂ   ammatory properties of the vagus nerve, 
popularized by the term ‘the inﬂ  ammatory reﬂ  ex’ [12]. 
While these interactions are likely to be involved in the 
development of septic encephalopathy, the exact mecha-
nisms remain inadequately understood.
One of the dilemmas in current sepsis research is the 
poor transferability of promising experimental ﬁ  ndings. 
Many pharmacological research strategies have failed a 
successful translation from ‘bench to bedside’. Th  is 
predica  ment is likely caused by an obvious disconnect 
between controlled animal models and the heterogeneous 
clinical sepsis syndrome observed in humans [13]. 
Experi  mental human studies, such as the study by van 
der Boogaard and colleagues, are limited by several 
factors. Endotoxemia is usually induced in a young, healthy 
population, and may rather present an acute intoxi  cation 
model than the multi-microbial or fungal infections 
observed in the sepsis syndrome. In such an experimental 
setting, the timing and dosage of LPS has to be limited 
based on safety issues, and therefore might not reach the 
threshold for the development of a signiﬁ  cant  BBB 
damage. Moreover, sepsis results from various causative 
etiologies, and susceptibility is inﬂ  uenced by premorbid 
factors, including ethnicity, gender, age, genetic defects 
and environmental factors.
Th  e advancement of clinical care for the septic patient 
will be an enormous challenge. Th   e belief that a single key 
mediator causes sepsis, and that its neutralization could be 
a cure for all patients with sepsis, seems erroneous [14]. In 
particular, pre-existing genetic and epi  genetic changes, 
mutations in genes that encode pattern-recognition 
receptors or inﬂ  ammatory mediators, may have an enor-
mous impact on the host’s susceptibility to sepsis. Inter-
disciplinary approaches involving both clinicians and basic 
scientists will be necessary to improve our knowledge of 
the underlying pathophysio  logy of sepsis and septic en-
cephalopathy. Such inter  disciplinary, large-scale programs 
involving surgery, genomics, proteomics, biostatistics, 
bioinformatics, compu  ta  tional biology and genetics are 
currently underway [15].
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